ban on sales of a cholesterol drug man by sanofi supporting a drug from amgen the ban wouldn't go into place for 30 days so the company's would have the opportunity to appeal this decision but a very big surprise decision here. patents fighting over this two cholesterol drugs that were improved in 2015. so far these drugs aren't huge money makers for eth of these companies. some estimates put potential shares around $330 million. for example, people estimate as we get more data on these drugs they could be huge block busters for both companies so this decision a huge surprise, a big knock for regeneral ron and sanofi. the question becomes what happens within these next 30 days. obviously they will very likely appeal but we haven't heard from the company's yet. could they reach some kind of settlement? all of this up in the air. >> pretty big moves in the after-hours. thanks so much from the nyse. obviously the drilling continues but in the meantime, what's your topic in biotech right now. >> i own giliat. i like a lot of names. today we had lee cooperman on as well he talked about
on a sanofi. i think they're going higher. >> up more than 1%. >> atw, unusual call ak it tift and abo activity. >> i dealt with the pullback. i stayed long and i'm going to keep it. >> jimmy? >> long the xrt. retail earnings this week. >> good stuff, guys. thanks. "power" starts now. >>> the fallout from the president's firing fbi director james comey continues, and there are two big questions that still need to be answered. number one, will anger over this move, even among some in the gop, damage the trump agenda? and, two, why doesn't the stock market seem to care about everything going on in d.c.? we will dig into both. plus, trouble in the magic kingdom. disney shares getting hit today, concerns about espn dragging down earnings, but are those concerns overdone? another good question. i'm brian sullivan. "power lunch" has answers. we start right now.
Fetching more results